ArticlePeerJ2025
Clinical diagnosis, treatment, and survival analysis of 61 cases of salivary duct carcinoma: a retrospective study.
Article in PeerJ, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Darolutamide Alone and in Combination With Goserelin in Androgen Receptor-Positive Salivary Gland Carcinoma: Results From the Phase II DISCOVARY Trial.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2026Trial
- Evolving Concepts in Salivary Duct Carcinoma: A Narrative Review.Oncology and therapy · 2026Review
- HER2-low and HER2-ultra-low salivary gland carcinomas: an exploratory study.Virchows Archiv : an international journal of pathology · 2026Article
- Testosterone and Androgen Receptor in Cancers with Significant Sex Dimorphism in Incidence Rates and Survival.Cancers · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: This study aims to investigate the clinicopathological features, treatment modalities, and prognostic factors associated with salivary duct carcinoma (SDC). Methods: A retrospective analysis was conducted on the clinicopathological data of 61 patients with SDC admitted to Shanxi Cancer Hospital from January 2010 to February 2024. This study focused on their demographic information, treatment regimens, clinical outcomes, and overall prognosis. Results: A total of 61 patients with SDC were included in this study, of whom 45 (73.77%) had primary tumors in the parotid gland, 44 (72.13%) were in stage IV at the initial visit, 35 (57.38%) had cervical lymph node metastases, and two (3.28%) had distant metastasis at the first visit. Immunohistochemical (IHC) staining showed that 54 cases (88.52%) were positive for androgen receptor (AR), and 25 cases (40.98%) were positive for human epidermal growth factor receptor 2 (HER-2). Two patients did not undergo surgical treatment due to distant metastasis and received palliative chemoradiotherapy. Fifty-nine patients underwent radical surgery, and of these, 52 (88.14%) received postoperative adjuvant treatment, including chemoradiotherapy or radiotherapy alone. The median overall survival (OS) time was 20 months for the non-surgery group ( Conclusion: SDC is a rare and highly aggressive malignancy with a poor prognosis. Surgical margins, American Joint Committee on Cancer (AJCC) stage, and treatment method were identified as adverse prognostic factors affecting the OS of patients with SDC. Radical surgery remains the primary treatment for salivary duct carcinoma while adjuvant therapy significantly reduces recurrence rates and improves survival. However, the overall prognosis remains challenging, highlighting the need for novel therapeutic strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.